Walmart’s U.S. same-store sales grew just 2.6% last quarter, its slowest pace in years, even as total revenue climbed.
Story Snapshot
- Walmart said U.S. comparable sales rose 2.6% in its fiscal second quarter.
- Total revenue increased about 5% and online sales stayed strong.
- Management cited pharmacy price limits as a key headwind on sales growth.
- Excluding that hit, core U.S. comps were stronger at about 3.4%.
What Walmart Reported And Why It Matters
Walmart reported that U.S. comparable sales rose 2.6% in the quarter ended July 31, 2026, marking the slowest increase in more than six years, according to multiple outlets. Overall revenue still rose, with the company’s earnings release showing top-line growth of roughly 5% and steady traffic gains. Because Walmart serves tens of millions of households, a softer same-store result is often read as a signal of strain on family budgets. That is why Wall Street and Main Street paid close attention.
Walmart also said its online business remained a bright spot. Global e-commerce sales rose 25%, showing shoppers still want speed, value, and delivery options even when they trim baskets in stores. The mix shift matters. Strong digital growth can lift total sales but can weigh on profit if shipping and fulfillment costs rise. For customers, the shift shows a hunt for convenience and deals. For investors, it raises questions about margins and how fast the online scale unlocks efficiency.
Pharmacy Pricing Rules Weighed On Results
Walmart tied part of the slowdown to health-and-wellness pricing pressure. Reporting on the results said new or tighter pharmacy price rules, including maximum fair price caps, reduced what the retailer could charge, which lowered comparable sales growth. Excluding that hit, core U.S. comparable sales were stronger at about 3.4%, according to coverage of the company’s figures. That split matters. It suggests a defined policy headwind, not a broad collapse in store demand across categories.
The exact share of the slowdown from consumer caution versus pharmacy price limits is not quantified in the public materials. Company comments and news reports point to both factors at work, but they do not break out how much each one drove the number. For families, pharmacy price caps can cut drug costs at the counter. For a retailer, those caps can reduce reported sales in a major health category. That math can make headlines look worse than the core shopping trend feels inside the store.
Why This Signals Pressure On Households
Same-store sales are a key yardstick because they track locations open at least a year and include online activity tied to those stores. That strips out growth from new space and shows true demand changes. When Walmart’s comparable sales slow, people often see it as a sign that paychecks are tight and prices still sting. That view is common even when revenue rises and transactions improve, because comparable sales speak directly to how much the average basket and trip are changing.
$WMT Walmart posted its worst single-day drop in more than four years.
Q2 US comparable sales grew 2.6% versus the 3.5% FactSet consensus. Q3 fiscal 2027 EPS guidance and full-year EPS guidance both came in below Wall Street expectations, offsetting Walmart's strong revenue…
— Finance Spot (@financespotnews) August 21, 2026
The public debate now turns to the cause and the path forward. If pharmacy pricing rules drove a chunk of the slowdown, lawmakers and agencies shaped this result. If shoppers are pulling back on general goods, inflation, high energy costs, and housing pressures could be to blame. Both right and left worry that policy choices often hit families first while big players adapt later. Walmart’s split story—solid revenue and e-commerce, slower comps—fits that concern and will be watched in coming quarters.
Sources:
wsj.com, upi.com, investing.com, finance.yahoo.com
